Stephen Krieger, MD, discusses how cognition is defined in multiple sclerosis and the tools to evaluate patients' cognitive performance.
AAN 2023: Cognition and Disease Modifying Therapies in Multiple Sclerosis
Stephen Krieger, MD, speaks to the known effects of disease-modifying therapies for multiple sclerosis on cognitive function, among other interventions.
Multiple sclerosis expert Stephen Krieger, MD, discusses what can be inferred from the latest data on disease-modifying therapies as it pertains to cognition, and the importance of assessing cognitive performance over time.
Advertisement
Advertisement
Trending on NeurologyLive
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
3
Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy
4
Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
5
